EP1589961A2 - Composition therapeutique destinee au traitement du virus hiv-1 et hiv-2 - Google Patents

Composition therapeutique destinee au traitement du virus hiv-1 et hiv-2

Info

Publication number
EP1589961A2
EP1589961A2 EP04706521A EP04706521A EP1589961A2 EP 1589961 A2 EP1589961 A2 EP 1589961A2 EP 04706521 A EP04706521 A EP 04706521A EP 04706521 A EP04706521 A EP 04706521A EP 1589961 A2 EP1589961 A2 EP 1589961A2
Authority
EP
European Patent Office
Prior art keywords
amount
present
desferrin
allocryptopine
chromium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04706521A
Other languages
German (de)
English (en)
Other versions
EP1589961A4 (fr
Inventor
Jelen Boguslaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Excyton-Excymer GmbH
Original Assignee
Excyton-Excymer GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/353,483 external-priority patent/US20030203045A1/en
Application filed by Excyton-Excymer GmbH filed Critical Excyton-Excymer GmbH
Publication of EP1589961A2 publication Critical patent/EP1589961A2/fr
Publication of EP1589961A4 publication Critical patent/EP1589961A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Definitions

  • a pharmaceutical mixture for blocking the HIV-l and/or HIV-2 virus replication in the CD4+ cells of the human immune system in all stages of that viral infection, and in AIDS also the method of production of the pharmaceutical mixture for blocking the HIV-l and HIV-2 virus replication in the CD4+ cells of the human immune system in all stages of that viral infection, and in AIDS.
  • HIV treatment and “treatment of HIV in a patient in need of such treatment” mean treating a patient with HIV-l and/or HIV-2.
  • blocking HIV virus replication means blocking HIV-l and/or HIV-2 virus replication.
  • HIV virus refers to the HIV-l and/or HIV-2 virus.
  • HIV infection refers to HIV-l and/or HIV-2 infection.
  • the subject of the invention is a pharmaceutical mixture for blocking the
  • HIV-l and HIV-2 virus replication in the CD4+ cells of the human immune system in all stages of that viral infection, and in AIDS also the method of production of the pharmaceutical mixture for blocking the HIV-l and HIV-2 virus replication in the CD4+ cells of the human immune system in all stages of that viral infection, and in AIDS.
  • the invented mixture has a particular application in treatment of the Acquired Immunodeficiency Syndrome, or AIDS. Synopsis of the Description
  • the subject of the invention is a pharmaceutical mixture for blocking the HIV-l and HIV-2 virus replication in the CD4+ cells of the human immune system in that viral infection, and in AIDS contains previously known carriers and/or auxiliary substances, as well as active substances, and it is characterized by the presence of at least 10 chemical substances as active substances, among them, allocryptopine, present in the amount from 1.0 mg to 10.0 mg; nimodipine, present in the amount from 20.0 mg to 100.0 mg; potassium iodide, present in the amount from 120.0 mg to 560.0 mg; potassium iodate, present in the amount from 30.0 mg to 140.0 mg; inulina, present in the amount from 125.0 mg to 375.0 mg; silver, present in the amount from 0.10 mg to 0.50 mg; zinc, present in the amount from 10.0 mg to 20.0 mg; chromium, present in the amount from 0.05 mg to 0.20 mg; orotic acid, present in the amount from 150.0 mg to 500.0 mg; desferrin, present in the amount from 100.0 mg
  • a pharmaceutical mixture and a method of its production of a therapeutic composition for blocking the HIV-l and HIV-2 virus replication in the CD4+ cells of the human immune system in all stages of that viral infection, and in AIDS for the treatment of HIV in a patient in need of such treatment the therapeutic composition comprising of pharmaceutically effective amounts of allocryptopine, nimodipine, potassium iodide, potassium iodate, inuline, silver, zinc, chromium, orotic acid and desferrin.
  • the pharmaceutical mixture and method further comprises pharmaceutically effective amounts of taraxasterol and B-sitosterol.
  • the invention pertains also to the method of production of the pharmaceutical mixture for blocking the HIV-l and HIV-2 virus replication in the CD4+ cells of the human immune system in all stages of that viral infection, and in AIDS, characterized by mixing, in the room temperature, of allocryptopine, in the amount from 1.0 mg to 10.0 mg; nimodipine, in the amount from 20.0 mg to 100.0 mg; potassium iodide, in the amount from 120.0 mg to 560.0 mg; potassium iodate, in the amount from 30.0 mg to 140.0 mg; inuline, in the amount from 125.0 mg to 375.0 mg; silver, in the amount from 0.10 mg to 0.50 mg; zinc, in the amount from 10.0 mg to 20.0 mg; chromium, in the amount from 0.05 mg to 0.20 mg; orotic acid, in the amount from 150.0 mg to 500.0 mg; desferrin, in the amount from 100.0 mg to 300.0 mg, until a mix approximating uniform substance is produced, subsequently pressed into tablets, and can also have
  • the premiss underlying the invention discussed here is the reasoning that the basis for the HIV- 1 and HIV-2 virus replication in the CD4+ cells of the human immune system is the exeitono-excimeric correlation between the HIV- 1 and HIV- 2 viruses and the CD4 cell of the human immune system.
  • HIV-l and HIV-2 replication to the patient's body.
  • allocryptopine is a nucleotide phosphodiesterase blocker
  • nimodipine is a calcium channel blocker
  • potassium iodide when combined with potassium iodate in the acidic environment, produces iodic free radicals
  • inuline is a polysaccharide which is not decomposed in the body
  • silver, zinc, and chromium are elements playing a role in the enzymatic processes
  • - desferrin chelates ferric ions, - orotic acid a the precursor of the nucleotide compounds.
  • the goal of the invention is supplying the pharmaceutical mixture for blocking the HIV-l and HIV-2 virus replication in the CD4+ cells of the human immune system.
  • the invention provides that the pharmaceutical mixture for blocking the
  • HW-l and HIV2 virus replication in the CD4+ cells of the human immune system in all stages of that viral infection, and in AIDS contains previously known carriers and/or auxiliary substances, as well as active substances, and it is characterized by the presence of at least 10 chemical substances as active substances, among them: - allocryptopine is present in the amount from 1.0 mg to 10.0 mg,
  • - nimodipine is present in the amount from 20.0 mg to 100.0 mg
  • - potassium iodide is present in the amount from 120.0 mg to 560.0 g,
  • - potassium iodate is present in the amount from 30.0 mg to 140.0 mg
  • - inuline is present in the amount from 125.0 mg to 375.0 mg
  • - silver is present in the amount from 0.10 mg to 0.50 mg
  • - zinc is present in the amount from 10.0 mg to 20.0 mg, -
  • - chromium is present in the amount from 0.05 mg to 0.20 mg
  • - orotic acid is present in the amount from 150.0 mg to 500.0 mg
  • -desferrin is present in the amount from 100.0 mg to 300.0 mg
  • - allocryptopine content is 10.0 mg
  • - and nimodipine content is 100.0 mg
  • - and inuline content is 375.0 mg, - and silver content is 0.50 mg,
  • - and desferrin content is 300.0 mg.
  • - and potassium iodide content is 340.0 mg
  • - and potassium iodate content is 85.0 mg
  • - and chromium content is 0.125 mg
  • - and orotic acid content is 325.0 mg
  • - and desferrin content is 200.0 mg.
  • - and potassium iodate content is 85.0 mg
  • - and inuline content is 250.0 mg
  • - and orotic acid content is 325.0 mg
  • - and desferrin content is 200.0 mg
  • - and inuline content is 125.0 mg, - and silver content is 0.10 mg,
  • - and orotic acid content is 250.0 mg
  • - and desferrin content is 100.0 mg
  • - and potassium iodate content is 30.0 mg
  • - and muline content is 125.0 mg
  • - and orotic acid content is 250.0 mg
  • - and desferrin content is 100.0 mg.
  • weight ratio of allocryptopine to nimodipine to potassium iodide to potassium iodate to inuline to silver to zinc to chromium to orotic acid to desferrin is generally maintained as 1 :20: 120:30: 125:0.1 : 10:0.05:250: 100. It is beneficial when the mixture of the ingredients has a form of a tablet, or coated tablet, or wafer, or suppository, or effervescent powder, or gel, or colloid
  • the mixture of the ingredients has a form of suspension, or syrup, or salt soluble in body fluids, or liquids for intramuscular or IV injections.
  • the production of the pharmaceutical mixture for blocking the HIV-l and HIV-2 virus replication in the CD4+ cells of the human immune system in all stages of that viral infection, and in AIDS is characterized by mixing, in the room temperature, the following ingredients: - - allocryptopine in the amount from 1.0 mg to lO.O mg,
  • - chromium in the amount from 0.05 mg to 0.20 mg
  • - orotic acid in the amount from 150.0 mg to 500.0 mg
  • - and potassium iodate content is 140.0 mg
  • - and inuline content is 375.0 mg
  • - and chromium content is 0.20 mg
  • - and orotic acid content is 500.0 mg
  • - and nimodipine content is 60.0 mg
  • - and potassium iodide content is 340.0 mg
  • - and zinc content is 15.0 mg
  • - and chromium content is 0.125 mg
  • - allocryptopine content is 1.0 mg
  • - and nimodipine content is 20.0 mg
  • - and inuline content is 125.0 mg, - and silver content is 0.10 mg,
  • - and orotic acid content is 250.0 mg
  • - and desferrin content is 100.0 mg.
  • the pharmaceutical mixture and method of making it may further comprise pharmaceutically effective amounts of taraxasterol and B-sitosterol.
  • the pharmaceutical mixture and method of making it is characterized by mixing, in the room temperature, of allocryptopine, in the amount from 1.0 mg to 10.0 mg; nimodipine, in the amount from 20.0 mg to 100.0 mg; potassium iodide, in the amount from 120.0 mg to 560.0 mg; potassium iodate, in the amount from
  • inuline in the amount from 125.0 mg to 375.0 mg
  • silver in the amount from 0.10 mg to 0.50 mg
  • zinc in the amount from 10.0 mg to 20.0 mg
  • chromium in the amount from 0.05 mg to 0.20 mg
  • orotic acid in the amount from 150.0 mg to 500.0 mg
  • desferrin in the amount from 100.0 mg to 300.0 mg
  • taraxasterol in the amount from 250-400 mg
  • B-sitosterol in the amount from
  • weight ratio of allocryptopine to nimodipine to potassium iodide to potassium iodate to inuline to silver to zinc to chromium to orotic acid to desferrin to taraxasterol to B-sitosterol is generally maintain as 1:20:120:30:125:0.1:10:0.05:250:100:350:400.
  • the mixture of the ingredients has a form of a tablet, or coated tablet, or wafer, or suppository, or effervescent powder, or gel, or a colloid solution.
  • the mixture of the ingredients has a form of suspension, or syrup, or salt soluble in body fluids, or liquids for intramuscular or
  • the beneficial effect of the pharmaceutical mixture in the invention is blocking the mechanism of attaching the gp 160 protein of the HIV virus capsule to the receptors of the CD4+ cells of the human immune system, as well as blocking the intracellular processes related to the HIV-l and HIV-2 virus replication.
  • Example No. 1 Content of the pharmaceutical mixture: - allocryptopine in the amount of 10.0 mg, - nimodipine in the amount of 100.0 mg,
  • the product can then be made into suspension, syrup, salt soluble in body fluids, or liquid for intramuscular or IV injections, also in ampules.
  • the mix can then be pressed into tablets, and can also have a form of coated tablets, or can be shaped into a wafer, a suppository, effervescent powder, gel, or colloid solution.
  • the product can then be made into suspension, syrup, salt soluble in body fluids, or liquid for intramuscular or IV injections, also in ampules.
  • pharmaceutically effective amount means an effective amount of the pharmaceutical mixture of the present invention (comprising a mixture of allocryptopine, nimodipine, potassium iodide, potassium iodate, inuline, silver, zinc, chromium, orotic acid and desferrin).
  • Actual dosage levels of the pharmaceutical composition of this invention can be varied so as to achieve the desired therapeutic response for a particular patient, compositions and mode of administration.
  • the selected dosage level will depend upon the activity of the particular compound, the route of administration, the severity of the condition being treated and the condition and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne un mélange pharmaceutique et un procédé de production d'une composition thérapeutique permettant de bloquer la réplication du virus VIH-1 et VIH-2 dans les cellules CD4+ du système immunitaire humain à toutes les étapes de cette infection virale et, dans le cas du sida, permettant de traiter le virus VIH chez un patient nécessitant un tel traitement.
EP04706521A 2003-01-29 2004-01-29 Composition therapeutique destinee au traitement du virus hiv-1 et hiv-2 Withdrawn EP1589961A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US353483 1994-12-09
US10/353,483 US20030203045A1 (en) 2002-04-30 2003-01-29 Therapeutic composition for the treatment of HIV-1 and HIV-2
PCT/US2004/002536 WO2004066954A2 (fr) 2003-01-29 2004-01-29 Composition therapeutique destinee au traitement du virus hiv-1 et hiv-2

Publications (2)

Publication Number Publication Date
EP1589961A2 true EP1589961A2 (fr) 2005-11-02
EP1589961A4 EP1589961A4 (fr) 2006-02-15

Family

ID=32823743

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04706521A Withdrawn EP1589961A4 (fr) 2003-01-29 2004-01-29 Composition therapeutique destinee au traitement du virus hiv-1 et hiv-2

Country Status (9)

Country Link
EP (1) EP1589961A4 (fr)
JP (1) JP2006516633A (fr)
KR (1) KR20050094461A (fr)
CN (1) CN1747726A (fr)
AU (1) AU2004206996A1 (fr)
CA (1) CA2514252A1 (fr)
RU (1) RU2005123957A (fr)
WO (1) WO2004066954A2 (fr)
ZA (1) ZA200505977B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101810625B (zh) * 2010-04-09 2012-05-23 上海新康制药厂 蒲公英甾醇的应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001949A1 (fr) * 1988-08-18 1990-03-08 The Australian National University Compositions a base d'inuline gamma
WO1990011761A1 (fr) * 1989-03-31 1990-10-18 The Children's Medical Center Corporation Traitement de la demence du sida, de la myelopathie et de la cecite
US4970212A (en) * 1982-05-18 1990-11-13 Nowicky Wassili Method of treating human illnesses which compromise the ability to mount an effective immunological response
WO1992021368A1 (fr) * 1991-06-06 1992-12-10 Life Sciences' Technologies, Inc. Composition et procede de traitement de maladies
WO2001000194A2 (fr) * 1999-06-29 2001-01-04 Jacobs Robert H Technique permettant d'optimiser une activite immune dans le traitement de maladies auto-immunes et de maladies immunes chroniques
WO2002080942A1 (fr) * 2001-04-04 2002-10-17 John Carter Composition pharmaceutique contenant du cuivre, de l'acide salicylique, de la vitamine c et du zinc, utile dans le traitement de differentes pathologies telles qu'une infection bacterienne ou virale
US20030203045A1 (en) * 2002-04-30 2003-10-30 Boguslaw Jelen Therapeutic composition for the treatment of HIV-1 and HIV-2

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2107502C1 (ru) * 1997-03-27 1998-03-27 Открытое акционерное общество "Ветеринарные препараты" Ветеринарный препарат, обладающий широким спектром действия, - йод однохлористый
RU2195277C2 (ru) * 2001-02-09 2002-12-27 Третьяков Василий Васильевич Способ лечения вич-инфекций

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970212A (en) * 1982-05-18 1990-11-13 Nowicky Wassili Method of treating human illnesses which compromise the ability to mount an effective immunological response
WO1990001949A1 (fr) * 1988-08-18 1990-03-08 The Australian National University Compositions a base d'inuline gamma
WO1990011761A1 (fr) * 1989-03-31 1990-10-18 The Children's Medical Center Corporation Traitement de la demence du sida, de la myelopathie et de la cecite
WO1992021368A1 (fr) * 1991-06-06 1992-12-10 Life Sciences' Technologies, Inc. Composition et procede de traitement de maladies
WO2001000194A2 (fr) * 1999-06-29 2001-01-04 Jacobs Robert H Technique permettant d'optimiser une activite immune dans le traitement de maladies auto-immunes et de maladies immunes chroniques
WO2002080942A1 (fr) * 2001-04-04 2002-10-17 John Carter Composition pharmaceutique contenant du cuivre, de l'acide salicylique, de la vitamine c et du zinc, utile dans le traitement de differentes pathologies telles qu'une infection bacterienne ou virale
US20030203045A1 (en) * 2002-04-30 2003-10-30 Boguslaw Jelen Therapeutic composition for the treatment of HIV-1 and HIV-2

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBASE [Online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1999, HARAGUCHI Y ET AL: "Inhibition of HIV-1 infection by zinc group metal compounds" XP002358702 Database accession no. EMB-1999309523 & ANTIVIRAL RESEARCH 1999 NETHERLANDS, vol. 43, no. 2, 1999, pages 123-133, ISSN: 0166-3542 *
DATABASE WPI Section Ch, Week 199849 Derwent Publications Ltd., London, GB; Class B05, AN 1998-581141 XP002358705 & RU 2 107 502 C1 (VETERINARY PREPARATIONS STOCK CO) 27 March 1998 (1998-03-27) *
DATABASE WPI Section Ch, Week 200318 Derwent Publications Ltd., London, GB; Class B05, AN 2003-181626 XP002358706 & RU 2 195 277 C2 (DOSYCHEV V M) 27 December 2002 (2002-12-27) *
GEORGIOU N A ET AL: "INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 REPLICATION IN HUMAN MONONUCLEAR BLOOD CELLS BY THE IRON CHELATORS DEFEROXAMINE, DEFERIPRONE AND BLEOMYCIN" JOURNAL OF INFECTIOUS DISEASES, CHICAGO, IL, US, vol. 181, no. 2, February 2000 (2000-02), pages 484-490, XP001027530 ISSN: 0022-1899 *
See also references of WO2004066954A2 *

Also Published As

Publication number Publication date
WO2004066954A2 (fr) 2004-08-12
CA2514252A1 (fr) 2004-08-12
RU2005123957A (ru) 2006-01-27
EP1589961A4 (fr) 2006-02-15
ZA200505977B (en) 2006-05-31
WO2004066954A3 (fr) 2005-03-17
JP2006516633A (ja) 2006-07-06
CN1747726A (zh) 2006-03-15
KR20050094461A (ko) 2005-09-27
AU2004206996A1 (en) 2004-08-12

Similar Documents

Publication Publication Date Title
JP2015510818A (ja) 薬物送達のための絹リザーバー
TW201731514A (zh) 治療及預防ｈｉｖ與ａｉｄｓ之方法
RU2007101695A (ru) Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
van der Spuy, S., Levy, DW & Levin Cimetidine in the treatment of herpesvirus infections
US20030203045A1 (en) Therapeutic composition for the treatment of HIV-1 and HIV-2
WO2018005914A1 (fr) Régimes et compositions pour le traitement des infections du vih et du sida
EP1589961A2 (fr) Composition therapeutique destinee au traitement du virus hiv-1 et hiv-2
US20230193219A1 (en) Superoxide dismutase compositions and methods
JPH05262654A (ja) 慢性疲労症候群治療剤
Zeidner et al. Treatment of FeLV-induced immunodeficiency syndrome (FeLV-FAIDS) with controlled release capsular implantation of 2′, 3′-dideoxycytidine
US5432187A (en) Benzimidazole anthelmintic in the treatment of microsporidial infections
JPH0415766B2 (fr)
RU2393872C2 (ru) Лечение вич инфекции посредством т-клеточной модуляции
CA2066134C (fr) Complexes d'acide polyadenylique avec de l'acide polyuridylique
JP2003527414A (ja) Ｃ型肝炎を治療するための薬剤
JP2004522783A (ja) 性的機能不全を予防および治療するための医薬の製造におけるｎ−アセチル−ｄ−グルコサミンの使用
Leake et al. Successful treatment of resistant cryptococcal meningitis with amphotericin B lipid emulsion after nephrotoxicity with conventional intravenous amphotericin B
US20230295585A1 (en) Superoxide dismutase compositions and methods
SU1114423A1 (ru) Способ лечени невралгии тройничного нерва
RU2188659C1 (ru) Фармацевтическая композиция для терапии человека, обладающая иммунотропным действием
REDDY'S FDA Drug Approvals
OA18864A (en) Médicament naturel contre le VIH/SIDA et autres pathologies
WO2018044822A1 (fr) Combinaisons, utilisations et traitements correspondants
Pomerantz et al. Therapy of human immunodeficiency virus infections
CN107226462A (zh) 多酸化合物、其制备方法和医药用途

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050805

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BOGUSLAW, JELEN

A4 Supplementary search report drawn up and despatched

Effective date: 20060102

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20061031

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070313